Hangzhou AGS MedTech Co., Ltd. (SHA:688581)
China
· Delayed Price · Currency is CNY 57.53
-0.59 (-1.02%)
At close: Mar 9, 2026
Hangzhou AGS MedTech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Operating Revenue | 597.21 | 632.86 | 506.09 | 368.92 | 305.1 | Upgrade
|
| Other Revenue | - | 3.78 | 2.65 | 2.2 | 0.37 | Upgrade
|
| Revenue | 597.21 | 636.63 | 508.75 | 371.11 | 305.47 | Upgrade
|
| Revenue Growth (YoY) | -6.19% | 25.14% | 37.09% | 21.49% | 77.64% | Upgrade
|
| Cost of Revenue | - | 180.84 | 149.86 | 119.38 | 108.54 | Upgrade
|
| Gross Profit | 597.21 | 455.79 | 358.89 | 251.73 | 196.92 | Upgrade
|
| Selling, General & Admin | - | 108.89 | 95.38 | 66.59 | 53 | Upgrade
|
| Research & Development | - | 59.21 | 41.25 | 31.46 | 24.19 | Upgrade
|
| Other Operating Expenses | 332.38 | 6.09 | 1.39 | 3.29 | 2.43 | Upgrade
|
| Operating Expenses | 332.38 | 173.69 | 140.17 | 101.63 | 79.83 | Upgrade
|
| Operating Income | 264.82 | 282.11 | 218.72 | 150.1 | 117.09 | Upgrade
|
| Interest & Investment Income | - | 55.23 | 28.91 | 2.59 | 2.52 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.32 | 0.69 | 11.1 | -4.24 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.9 | 1.19 | -1.05 | -0.84 | -0.14 | Upgrade
|
| EBT Excluding Unusual Items | 263.92 | 338.85 | 247.28 | 162.95 | 115.23 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 2.08 | 0.41 | -7.19 | 1.09 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.19 | -0.35 | -0.14 | -0.01 | Upgrade
|
| Asset Writedown | - | -0.02 | -0.46 | -0 | -0.14 | Upgrade
|
| Other Unusual Items | - | 2.87 | 4.78 | 9.94 | 3.79 | Upgrade
|
| Pretax Income | 263.92 | 343.6 | 251.67 | 165.56 | 119.97 | Upgrade
|
| Income Tax Expense | 41.1 | 50.21 | 34.43 | 20.6 | 15.17 | Upgrade
|
| Net Income | 222.82 | 293.39 | 217.24 | 144.96 | 104.8 | Upgrade
|
| Net Income to Common | 222.82 | 293.39 | 217.24 | 144.96 | 104.8 | Upgrade
|
| Net Income Growth | -24.05% | 35.06% | 49.86% | 38.32% | 131.68% | Upgrade
|
| Shares Outstanding (Basic) | 80 | 81 | 73 | 61 | 61 | Upgrade
|
| Shares Outstanding (Diluted) | 80 | 81 | 73 | 61 | 61 | Upgrade
|
| Shares Change (YoY) | -0.18% | 11.02% | 19.46% | - | - | Upgrade
|
| EPS (Basic) | 2.77 | 3.64 | 2.99 | 2.39 | 1.72 | Upgrade
|
| EPS (Diluted) | 2.77 | 3.64 | 2.99 | 2.39 | 1.72 | Upgrade
|
| EPS Growth | -23.92% | 21.65% | 25.44% | 38.60% | 131.71% | Upgrade
|
| Free Cash Flow | - | 266.19 | 169.88 | 96.26 | 102.59 | Upgrade
|
| Free Cash Flow Per Share | - | 3.30 | 2.34 | 1.58 | 1.69 | Upgrade
|
| Dividend Per Share | - | 1.373 | 1.036 | 0.543 | - | Upgrade
|
| Dividend Growth | - | 32.62% | 90.77% | - | - | Upgrade
|
| Gross Margin | 100.00% | 71.59% | 70.54% | 67.83% | 64.47% | Upgrade
|
| Operating Margin | 44.34% | 44.31% | 42.99% | 40.45% | 38.33% | Upgrade
|
| Profit Margin | 37.31% | 46.09% | 42.70% | 39.06% | 34.31% | Upgrade
|
| Free Cash Flow Margin | - | 41.81% | 33.39% | 25.94% | 33.59% | Upgrade
|
| EBITDA | 272.79 | 290.07 | 225.29 | 154.82 | 121.17 | Upgrade
|
| EBITDA Margin | 45.68% | 45.56% | 44.28% | 41.72% | 39.67% | Upgrade
|
| D&A For EBITDA | 7.96 | 7.96 | 6.56 | 4.72 | 4.07 | Upgrade
|
| EBIT | 264.82 | 282.11 | 218.72 | 150.1 | 117.09 | Upgrade
|
| EBIT Margin | 44.34% | 44.31% | 42.99% | 40.45% | 38.33% | Upgrade
|
| Effective Tax Rate | 15.57% | 14.61% | 13.68% | 12.44% | 12.64% | Upgrade
|
| Revenue as Reported | - | 636.63 | 508.75 | 371.11 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.